SCHEMBL23999630

SCHEMBL23999630

Cc1cc(Oc2ccc(NC(=O)c3ccc(Nc4ccncc4)cc3)cc2)ccn1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.55
▸ POLB P06746 2/20 0.54
▸ MAPT P10636 2/20 0.54
▸ MAPK13 O15264 2/20 0.53
▸ SMN1; SMN2 Q16637 2/20 0.53
▸ STAT3 P40763 1/20 0.53
▸ KMT2A Q03164 2/20 0.52
▸ RAB9A P51151 2/20 0.52
▸ NPC1 O15118 1/20 0.52
▸ KDM4E B2RXH2 2/20 0.51
▸ L3MBTL1 Q9Y468 1/20 0.51
▸ MAPK1 P28482 2/20 0.50
▸ ALDH1A1 P00352 1/20 0.50
▸ TP53 P04637 1/20 0.50
▸ MITF O75030 1/20 0.50
▸ DNMT1 P26358 1/20 0.50
▸ DNMT3A Q9Y6K1 1/20 0.50
▸ GAA P10253 1/20 0.48
▸ GALR3 O60755 1/20 0.46
▸ PGR P06401 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23999626 0.95 LMNA (0.55) LMNAPOLBMAPTMAPK13SMN1; SMN2
SCHEMBL23999625 0.94 RAB9A (0.53) LMNAPOLBMAPTMAPK13SMN1; SMN2
SCHEMBL24003736 0.88 RAF1 (0.51) LMNAPOLBMAPTMAPK13SMN1; SMN2
SCHEMBL30232529 0.88 RAF1 (0.51) LMNAPOLBMAPTMAPK13SMN1; SMN2
SCHEMBL23999634 0.88 POLB (0.68) LMNAPOLBMAPTSMN1; SMN2STAT3
SCHEMBL23999629 0.86 MAPT (0.63) LMNAPOLBMAPTSMN1; SMN2STAT3
SCHEMBL23999624 0.86 MAPT (0.63) LMNAPOLBMAPTSMN1; SMN2STAT3
SCHEMBL19888734 0.85 PGR (0.65) LMNAMAPTMAPK13SMN1; SMN2KMT2A
SCHEMBL24006303 0.85 MAPK13 (0.61) LMNAMAPK13SMN1; SMN2KMT2ARAB9A
SCHEMBL23999771 0.82 MEN1 (0.45) LMNAPOLBMAPTSMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230183226-A1 AKT3 MODULATORS Georgiamune Inc. 2023-06-15 — — US disclosed
US-20230183226-A1 AKT3 MODULATORS Georgiamune Inc. 2023-06-15 — — US disclosed
WO-2023081854-A1 AKT3 MODULATORS GEORGIAMUNE LLC (US) 2023-05-11 — — WO disclosed
WO-2021226519-A1 AKT3 MODULATORS GEORGIAMUNE LLC (US) 2021-11-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230183226-A1 AKT3 MODULATORS AKT3, AKT2, MTOR LMNA 1249/4885POLB 2609/4885MAPT 3999/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback